Formulations for improving scalp microbiome

Abstract

An accord composition for improving the scalp microbiome is provided. Such accord compositions comprise hinokitiol and at least one synergistic compound. Consumer products and methods of use for the consumer products are also provided.

Description

[0001] Attorney Docket No.: 071950.0475

[0002] FORMULATIONS FOR IMPROVING SCALP MICROBIOME

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims the benefit of priority to U.S. Provisional Application Serial No. 63 / 735,849, filed December 18, 2024, the contents of which are incorporated herein by reference in its entirety.

[0005] FIELD

[0006] The presently disclosed subject matter relates to accord compositions for improvement of the scalp microbiome, consumer products, and uses thereof.

[0007] BACKGROUND

[0008] The surface of the scalp and the hair follicle is an ecosystem of various microorganisms, known as the scalp microbiome. These microorganisms are a combination of fungal and bacterial organisms, whose abundance in the optimal ratios is necessary for maintaining scalp health. Common bacteria found on the scalp microbiome include Staphylococcus epidermidis (S. epidermidis) and Cutibacterium acnes (C. acnes), while common fungi comprise the Malassezia yeasts, Malassezia restricta (M reslricla) and Malassezia globosa (M globosa) (Townsend, N., et al. J Clin Aesthet Dermatol. 16(10 Suppl 1):S4).

[0009] Maintaining the microbiome of the scalp is important in preserving the health of the scalp. Environmental factors, such as humidity, air pollution, exercise, and exposure to chemicals, interpersonal factors such as age, sex, ethnicity, and hair washing routine, and general health and diet can all influence the health of the microbiome. An imbalance of the microorganisms in the microbiome can lead to a variety of conditions impacting the scalp. For example, dandruff has previously been linked with a higher incidence of M. restricta and S. epidermidis, as well as lower incidence of C. acnes (Clavaud, C., et al. PLoS ONE 8(3): e58203). These conditions typically result in various symptoms such as scalp flakiness, malodor, and itchiness.

[0010] Accords for use in consumer products, such as shampoos, which target bacteria or fungi on the scalp, would allow consumers to maintain their scalp microbiome. There remains a need in the art for such formulations.

[0011] ACTIVE 513686434.1 1 Attorney Docket No.: 071950.0475

[0012] SUMMARY OF THE INVENTION

[0013] The purpose and advantages of the disclosed subject matter will be set forth in and are apparent from the description that follows, as well as will be learned by practice of the disclosed subject matter. Additional advantages of the disclosed subject matter will be realized and attained by the devices particularly pointed out in the written description and claims hereof, as well as from the appended drawings.

[0014] To achieve these and other advantages and in accordance with the purpose of the disclosed subject matter, as embodied and broadly described, the disclosed subject matter provides an accord composition for improving the scalp microbiome comprising hinokitiol and at least one synergistic compound.

[0015] In certain embodiments, hinokitiol is present in the accord composition in an amount of from about 0.1% to about 20% by weight of the accord composition. In certain embodiments, the at least one synergistic compound is present in the accord composition in an amount of 50% to about 99.9% by weight of the accord composition. In particular embodiments, the at least one synergistic compound is present in the accord composition in an amount of 0.01% to about 50% by weight of the accord composition.

[0016] In certain embodiments, the at least one synergistic compound comprises a first synergistic compound and at least one additional synergistic compound. In particular embodiments, the first synergistic compound is present in an amount of from about 0.1% to about to about 75% by weight of the accord composition. In certain embodiments, the at least one additional synergistic compound is present in an amount of from about 25% to about 70% by weight of the accord composition.

[0017] In certain embodiments, the first synergistic compound is geraniol or musk T. In particular embodiments, the first synergistic compound is geraniol. In certain embodiments, the at least one additional synergistic compounds are selected from the group consisting of beta-ionone, aldehyde C-8, citral, 1-dihydro citronellol, heptanoic acid, nonadi en-l-ol-trans-2- Cis 6, caprylic acid, undecalactone gamma, decalactone delta, benzyl phenyl acetate, hexyl cinnamic aldehyde, phenyl ethyl alcohol, thymol, laurinal, florol, alcohol C-12, alcohol C-8, L-citronellal, geraniol, musk T, nutmeg oil, pinene beta, linalool, and citronellol. In certain embodiments, the at least one additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T. In particular embodiments, the at least one additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, citronellol, and musk T.

[0018] ACTIVE 513686434.1 2 Attorney Docket No.: 071950.0475

[0019] In certain embodiments, the composition targets at least one bacteria or fungi species. In certain embodiments, the fungi species are selected from the group consisting of Cladosporium halotolerans-sphaerospermum (C. halotolerans-sphaerospermum), Cladosporium sp, Malassezia arunalokei (M arunalokei), Malassezia caprae (M caprae), Malassezia globosa (M. globosa), Malassezia restricta (M. reslricla . Malassezia slooffiae (M slooffiae), Malassezia sp, Vishniacozyma taibaiensis (V. taibaiensis), and combinations thereof. In particular embodiments, the bacteria species are selected from the group consisting of Cornyebacterium kroppenstedtii (C. kroppenstedtii), Cutibacterium acnes (C. acnes), Cutibacterium humerusii (C. humerusii), Gordonia terrae (G. lerrae , Moraxella osloensis (M osloensis), Staphylococcus capitis-caprae (S. capitis-caprae), Staphylococcus caprae (S. caprae), Staphylococcus caprae-saccharolyticus (S. caprae-saccharolyticus) Stapphylococcus epidermis (S. epidermidis), Staphylococuccus saccharolyticus (S. capitis- saccharolyticus), L. clevelandensis, P. Uni, P. antartica and combinations thereof.

[0020] The disclosed subj ect matter further provides a consumer product for improving scalp microbiome comprising a consumer product base and an accord composition, wherein the accord composition comprises hinokitiol and at least one synergistic compound.

[0021] In certain embodiments, hinokitiol is present in the accord composition in an amount of from about 0.1% to about 20% by weight of the accord composition. In certain embodiments, the at least one synergistic compound is present in the accord composition in an amount of 50% to about 99.9% by weight of the accord composition. In particular embodiments, the at least one synergistic compound is present in the accord composition in an amount of 0.01% to about 50% by weight of the accord composition.

[0022] In certain embodiments, the at least one synergistic compound comprises a first synergistic compound and at least one additional synergistic compound. In particular embodiments, the first synergistic compound is present in an amount of from about 0.1% to about to about 75% by weight of the accord composition. In certain embodiments, the at least one additional synergistic compound is present in an amount of from about 25% to about 70% by weight of the accord composition.

[0023] In certain embodiments, the first synergistic compound is geraniol or musk T. In particular embodiments, the first synergistic compound is geraniol. In certain embodiments, the at least one additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T. In particular embodiments, the at least one additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, citronellol, and musk T.

[0024] ACTIVE 513686434.1 3 Attorney Docket No.: 071950.0475

[0025] In certain embodiments, the accord composition is present in the composition in an amount of about 0.01% to about 10% by weight of the consumer product.

[0026] In particular embodiments, the consumer product is selected from the group consisting shampoos, conditioners, dry shampoos, hair masks, hair oils, hair serums, hair wax, hair pomade, hair gel, hair cream, hair creme, hair clay, hair powders, hair mousse, hair lotion, hair musk, hair texturizer, heat protectant spray, sea salt spray, scalp lotion, and combinations thereof.

[0027] In certain embodiments, the present disclosure provides a method for improving the scalp microbiome, comprising treating the scalp with the consumer product.

[0028] In certain embodiments, after treating the scalp with the consumer product the bacterial-to-fungal ratio of the scalp is increased. In particular embodiments, the fungi species are selected from the group consisting of Cladosporium halotolerans-sphaerospermum (C halotolerans-sphaerospermum), Cladosporium sp, Malassezia arunalokei (M. arunalokei), Malassezia caprae (M. caprae), Malassezia globosa (M. globosa), Malassezia restricta (M reslricla . Malassezia slooffiae (M slooffiae), Malassezia sp, Vishniacozyma taibaiensis (V. taihaiensis), and combinations thereof. In particular embodiments, the bacteria species are selected from the group consisting of Corny ebacterium kroppenstedtii (C. kroppenstedtii), Cutibacterium acnes (C acnes), Cutibacterium humerusii (C humerusii), Gordonia terrae (G. terrae), Moraxella osloensis (M osloensis), Staphylococcus capitis-caprae (S. capitis-caprae), Staphylococcus caprae (S. caprae), Staphylococcus caprae-saccharolyticus (S. caprae- saccharolyticus) , Stapphylococcus epidermis (S. epidermidis), Staphylococuccus saccharolyticus (S. capitis- saccharolyticus), L. clevelandensis, P. Uni, P. antartica and combinations thereof.

[0029] In certain embodiments, after treating the scalp with the consumer product there is a decrease in sebum production, decrease in scalp flakiness, decrease in scalp malodor, decrease in scalp irritation, decrease in scalp sensitivity, increase in hair growth, increase in smoothness or silkiness, increase in bounciness, increase in overall hair quality, and combinations thereof.

[0030] It is to be understood that both the foregoing general description and the following detailed description and drawings are examples and are provided for purpose of illustration and not intended to limit the scope of the disclosed subject matter in any manner.

[0031] ACTIVE 513686434.1 4 Attorney Docket No.: 071950.0475

[0032] BRIEF DESCRIPTION OF THE DRAWINGS

[0033] The subject matter of the application will be more readily understood from the following detailed description when read in conjunction with the accompanying drawings, in which:

[0034] FIG. 1 provides the minimum inhibition concentration of Accords A-D with M. restricta and S. epidermidis.

[0035] FIG. 2 shows the bacterial to fungal ratio at the baseline, after placebo shampoo use, and after active shampoo use.

[0036] FIG. 3 A shows the bacterial load at the baseline, after placebo shampoo use, and after active shampoo use.

[0037] FIG. 3B illustrates the bacterial load at the baseline, after placebo shampoo use, and after active shampoo use of participants with dry scalps and participants with oily scalps.

[0038] FIG. 4A shows the fungal load at the baseline, after placebo shampoo use, and after active shampoo use.

[0039] FIG. 4B illustrates the fungal load at the baseline, after placebo shampoo use, and after active shampoo use of participants with dry scalps and participants with oily scalps.

[0040] FIG. 5A shows Shannon diversity index of the bacterial load at the baseline, after placebo shampoo use, and after active shampoo use.

[0041] FIG. 5B shows Shannon diversity index of the fungal load at the baseline, after placebo shampoo use, and after active shampoo use.

[0042] FIG. 6A shows Bray-Curtis dissimilarity of the bacterial load at the baseline, after placebo shampoo use, and after active shampoo use.

[0043] FIG. 6B shows Bray-Curtis dissimilarity of the fungal load at the baseline, after placebo shampoo use, and after active shampoo use.

[0044] FIG. 7A demonstrates bacterial absolute abundance at the baseline, after placebo shampoo use, and after active shampoo use. To illustrate the absolute abundance of C. acnes across the full spectrum of the x-axis, the x-axis has been adjusted to display absolute abundance in two ranges: 0 to 6,000 and 20,000 to 60,000. While the x-axis has been adjusted, the absolute abundance spans the full range between 6,000 and 20,000.

[0045] FIG. 7B demonstrates bacterial relative abundance at the baseline, after placebo shampoo use, and after active shampoo use. To illustrate the relative abundance of C. acnes across the full spectrum of the x-axis, the x-axis has been adjusted to display relative abundance

[0046] ACTIVE 513686434.1 5 Attorney Docket No.: 071950.0475 in two ranges: 0% to 10% and 60% to 100%. While the x-axis has been adjusted, the relative abundance spans the full range between 10% and 60%.

[0047] FIG. 7C shows the fungal relative abundance at the baseline, after placebo shampoo use, and after active shampoo use. To illustrate the relative abundance of M. restricta across the full spectrum of the x-axis, the x-axis has been adjusted to display relative abundance in two ranges: 0% to 10% and 60% to 100%. While the x-axis has been adjusted, the relative abundance spans the full range between 10% and 60%.

[0048] FIG. 7D shows the fungal absolute abundance at the baseline, after placebo shampoo use, and after active shampoo use.

[0049] FIG. 7E shows the bacterial absolute abundance at the baseline, after placebo shampoo use, and after active shampoo use of dry and oily scalp participants.

[0050] FIG. 7F shows the fungal absolute abundance at the baseline, after placebo shampoo use, and after active shampoo use of dry and oily scalp participants.

[0051] FIG. 8A shows the correlation of the absolute abundance of M. restricta to the Adherent Flaking Score.

[0052] FIG. 8B shows the correlation of the absolute abundance of C. acnes to the Adherent Flaking Score.

[0053] FIG. 8C illustrates the difference in flakiness abundance at the baseline, after placebo shampoo use, and after active shampoo use for oily and dry scalps.

[0054] FIG. 9A shows the response to the self-reported survey at the baseline, after placebo shampoo use, and after active shampoo use for oily and dry scalps.

[0055] FIG. 9B demonstrates the ANOVA analysis of the self-reported survey at the baseline, after placebo shampoo use, and after active shampoo use.

[0056] FIG. 10A shows the response to the self-reported survey at the baseline, after placebo shampoo use, and after active shampoo use for oily and dry scalps.

[0057] FIG. 10B demonstrates the ANOVA analysis of the self-reported survey at the baseline, after placebo shampoo use, and after active shampoo use.

[0058] DETAILED DESCRIPTION

[0059] Accord compositions for improving the health of the scalp microbiome are provided herein. Such accord compositions can be used in consumer products. These and other aspects of the disclosed subject matter are discussed in more detail.

[0060] For clarity and not by way of limitation, this detailed description is divided into the

[0061] ACTIVE 513686434.1 6 Attorney Docket No.: 071950.0475 following sub-portions:

[0062] 1. Definitions;

[0063] 2. Scalp Microbiome;

[0064] 3. Compositions;

[0065] 4. Consumer Products; and

[0066] 5. Methods of Treating the Scalp Microbiome.

[0067] 1. Definitions

[0068] The terms used in this specification generally have their ordinary meanings in the art, within the context of this disclosure and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions and methods of the disclosure and how to make and use them.

[0069] As used herein, the use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and / or the specification can mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

[0070] Still further, the terms “having,” “including,” “containing” and “comprising” are interchangeable and one of skill in the art is cognizant that these terms are open ended terms.

[0071] The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within three or more than three standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value or within ±20% of a given value, preferably within ±10%, more preferably within ±5%, and most preferably within ±1%. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within five-fold, and more preferably within two-fold, of a value.

[0072] As used herein, the term “accord” refers to a composition that contains one or more different compounds that creates a specific smell, odor or scent. One or more “accords” can be utilized as part of a composition.

[0073] As used herein, the phrase “consumer product” or “end product” refers to composition that is in a form ready for use by the consumer for the marketed indication. A solvent suitable for use in a consumer product is a solvent that, when combined with other components of the

[0074] ACTIVE 513686434.1 7 Attorney Docket No.: 071950.0475 end product, will not render the consumer product unfit for its intended consumer use.

[0075] 2. Scalp Microbiome

[0076] The scalp microbiome is an environment comprised of various microorganisms. The said microorganisms include a variety of bacteria and fungi in an estimated 3 to 1 ratio of bacteria-to-fungi. For example, as disclosed in the evaluations provided herein the bacterial load is greater than the fungal load on the scalp microbiome. An imbalance in the concentrations of the bacteria and fungi can lead to the decline of scalp health, resulting in a variety of common scalp conditions and diseases. The accord compositions of the present disclosure target at least one fungi or bacteria species on the scalp to alleviate the scalp conditions and diseases.

[0077] Common scalp conditions or diseases which are caused by an imbalance on the scalp microbiome are known in the art. These include conditions or diseases such as alopecia areata, dandruff, seborrheic dermatitis, scalp psoriasis, and folliculitis decalvans (Shah, R. R., et al. Arch Dermatol. Res. 316(8):495). As a result of an imbalance of the scalp microbiome, symptoms such as flakiness, itchiness, and malodor of the scalp will develop. In particular embodiments, the accord compositions target at least one bacteria or fungi species on the scalp to improve at least one symptom selected from the group consisting of flakiness, itchiness, and malodor of the scalp.

[0078] The common bacteria of the scalp include bacteria from the Firmicutes, Proteobacteria, and Actinobacteria phyla. Bacteria of the Firmicutes phyla found on the scalp comprise bacteria of the Staphylococcus genera, such as S. epidermidis, bacteria of the Actinobacteria phyla comprise bacteria of the Cutibacterium genera, such as C. acnes, and the Lawsonella genera, such as Lawsonella clevelandensis (L. clevelandensis), and bacteria of the Proteobacteria phyla comprise bacteria of the Pseudomonas genera, such as Pseudomonas Uni (P. Uni) and Pseudomonas antartica (P. an tar ti co) (Watanabe, K., et al. Bioscience, Biotechnology, and Biochemistry, 84(12):2585).

[0079] These bacteria, such as S. epidermidis and C. acnes are regularly found on the human skin as part of the microbiome. S. epidermidis, for example, is a coagulase-negative, grampositive bacteria which is the most common bacteria detected on the human epithelia. While it is generally harmless, under certain conditions, such as contamination on a medical device, S. epidermic can cause infections in the human body (Otto, M. Nat Rev Microbiol. 7(8):555). The balance of the S. epidermidis on the human scalp is, therefore, especially important for maintaining scalp health.

[0080] ACTIVE 513686434.1 8 Attorney Docket No.: 071950.0475

[0081] Fungi found on the scalp include fungi from the Malassezia genus of the phylum Basidiomycota. These fungi, which are yeasts, are typically M. restricta and M. globosa. (Townsend, N., et al. J Clin Aesthet Dermatol. 16(10 Suppl 1):S4). Malassezia spp. are commonly isolated fungi on human skin, with M. restricta being the most prevalent. The presence of this yeast-like fungi is generally thought to cause dandruff, among other scalp conditions (Park, M., et al. Scientific Reports. 8: 12086). Thus, maintaining optimal concentrations ofM. restricta is necessary for supporting the health of the scalp.

[0082] The accord compositions of the present disclosure, as described in more detail below in Section 3, target at least one bacteria species or fungi on the scalp, as shown by the minimum inhibition concentration (MIC) data disclosed herein. In certain embodiments, the accord compositions increase the bacterial-to-fungal ratio, where fungal load decreases. In certain embodiments, the accord compositions target at least one bacteria species and at least one fungi species on the scalp microbiome. In certain embodiments, the accord compositions of the present disclosure target two bacteria or fungi species on the scalp microbiome.

[0083] In certain embodiments, the accord compositions target at least one bacteria species or fungi species to decrease scalp flakiness, decrease scalp malodor, decrease scalp irritation, decrease scalp sensitivity, increase hair growth, increase smoothness or silkiness, increase bounciness, increase overall hair quality, and combinations thereof.

[0084] In particular embodiments, the accord compositions target at least one bacteria species. The bacteria species are selected from the group consisting of Cornyebacterium kroppenstedtii (C. kroppenstedtii), Cutibacterium acnes (C. acnes), Cutibacterium humerusii (C. humerusii), Gordonia terrae (G. terrae), Moraxella osloensis (M. osloensis), Staphylococcus capitis-caprae (S. capitis-caprae), Staphylococcus caprae (S. caprae), Staphylococcus caprae-saccharolyticus (S. caprae-saccharolyticus) , Stapphylococcus epidermis (S. epidermidis), Staphylococuccus saccharolyticus (S. capitis- saccharolyticus), L. clevelandensis, P. Uni, P. antartica, and combinations thereof In certain embodiments, the bacteria are selected from the group consisting of Cornyebacterium kroppenstedtii, C. acnes, Cutibacterium humerusii, Gordonia terrae, Moraxella osloensis, Staphylococcus capitis- caprae, Staphylococcus caprae, Staphylococcus caprae-saccharolyticus, S. epidermidis, Staphylococuccus saccharolyticus, and combinations thereof. In particular embodiments, the accord compositions target C. acnes and S. epidermidis. In particular embodiments, the accord compositions target C. acnes. In particular embodiments, the accord compositions target S.

[0085] ACTIVE 513686434.1 9 Attorney Docket No.: 071950.0475 epidermidis.

[0086] In certain embodiments, the accord compositions target at least one fungi species. The fungi are selected from Cladosporium halotolerans-sphaerospermum (C. halotolerans- sphaerospermum), Cladosporium sp, Malassezia arunalokei (M arunalokei), Malassezia caprae (M caprae), Malassezia globosa (M. globosa), Malassezia restricta (M reslricla . Malassezia slooffiae (M slooffiae), Malassezia sp, Vishniacozyma taibaiensis (V. taibaiensis), and combinations thereof. In certain embodiments, the accord compositions are target at least one of restricta, Cladosporium sp. and M. globosa.

[0087] 3. Compositions

[0088] The present disclosure provides accord compositions for improvement of the scalp microbiome. The accord compositions comprise hinokitiol and at least one synergistic compound. The hinokitiol and the at least one synergistic compound are combined to form an accord composition with targets at least one bacteria or fungi species on the scalp microbiome.

[0089] 3,1 Hinokitiol

[0090] Hinokitiol, also known as beta-thujaplicin, is a naturally occurring monoterpenoid compound derived from evergreen trees having the following structure:

[0091] This well-known bioactive compound has anti-bacterial and anti-fungal properties, so it is commonly used in both drugs and cosmetics as a preservative.

[0092] In fact, hinokitiol is active in low concentrations against both the fungi M. restricta and the bacteria S. epidermidis. In certain embodiments, hinokitiol is effective against M. restricta at a minimum inhibition concentration of about 7.8 ppm. In certain embodiments, hinokitiol is effective against S. epidermidis at a minimum inhibition concentration of about 15.6 ppm.

[0093] The accord compositions of the present disclosure comprise hinokitiol for the improvement of the scalp microbiome due to its anti-bacterial and anti-fungal properties. Thus, hinokitiol is considered an active ingredient in the accord compositions. In particular embodiments, the accord composition comprises hinokitiol in amount of from about 0.1% to about 20%, from about 1% to about 15 %, from about 2.5% to about 10%, from about 5% to about 15%, from about 6% to about 15%, from about 6.5% to about 8%, from about 4% to

[0094] ACTIVE 513686434.1 10 Attorney Docket No.: 071950.0475 about 7%, or from about 4.5% to about 6.5% by weight of the accord composition. In alternative embodiments, the accord composition comprises hinokitiol in amount of from about 0.1% to about 20%, from about 0.5% to about 15 %, from about 1.0% to about 10%, or from about 2% to about 5.5% by weight of the accord composition.

[0095] 3,2 Synergistic Compounds

[0096] The accord compositions additionally comprise synergistic compounds. These compounds are used with hinokitiol to synergistically improve the bacterial and fungal activity of the accord composition. While some synergistic compounds exhibit anti-bacterial and / or anti-fungal activity independent of hinokitiol, others only exhibit anti-bacterial and / or antifungal activity when used in combination with hinokitiol. The addition of the synergistic compounds to the accord composition allows for a lower concentration of hinokitiol to be used in the accord composition, while retaining the activity of the accord composition.

[0097] The synergistic compounds are selected from the group consisting of carvacrol, damascene alpha, capric acid, octalactone gamma, sandalwood, amyl cinnamic aldehyde, cinnamic aldehyde, cinnamic acid, damascenone total, damascene delta, ethyl caprate, ionone beta, ionone alpha, lilial, lauric acid, alcohol C-10, alcohol C-9, aldehyde C-10, aldehyde C-9, aldehyde C-8, benzyl benzoate, canthoxal, citral, citronellyl acetate, citronellyl nitrile, decalactone gamma, decen-l-ol, / -dihydro citronellol, hedirosa, heptanoic acid, menthol, trans- 2-cis-6-nonadien-l-ol-, nonalactone delta, nonenal cis 6, origanum oil, perilla aldehyde, vetiverol ECO, caprylic acid, cinnamon bark oil, cinnamon leaf oil, cinnamyl acetate, dodecalactone delta, dodecalactone gamma, undecalactone gamma, decalactone delta, benzyl phenyl acetate, benzaldehyde, hexyl cinnamic aldehyde, 2-cyclohexylidene-2- phenylacetonitrile, phenyl ethyl alcohol, thymol, laurinal, florol, alcohol C-12, alcohol C-8, L- citronellal, geraniol, musk T, nutmeg oil, pinene beta, citronellol, and linalool.

[0098] In certain embodiments, the synergistic compound, which only exhibit anti-bacterial and anti-fungal activity in combination with hinokitiol are selected from ionone beta, aldehyde C-8, citral, 1-dihydro citronellol, heptanoic acid, nonadien-l-ol-trans-2-Cis 6, caprylic acid, undecalactone gamma, decalactone delta, benzyl phenylacetate, hexyl cinnamic aldehyde, phenyl ethyl alcohol, thymol, laurinal, florol, alcohol C-12, alcohol C-8, L-citronellal, geraniol, musk T, nutmeg oil, pinene beta, linalool, and citronellol.

[0099] In certain embodiments, the accord composition comprises one synergistic compound. In alternative embodiments, the accord composition comprises at least two, at least three, at least four, at least five, at least six, or at least seven synergistic compounds. In

[0100] ACTIVE 513686434.1 11 Attorney Docket No.: 071950.0475 particular embodiments, the accord composition comprises a first synergistic compound and at least one additional synergistic compound. In alternative embodiments, the accord composition comprises two, three, four, five, six, or seven additional synergistic compounds. In particular embodiments, the accord composition comprises a first synergistic and at least two additional synergistic compounds. In certain embodiments, the accord composition comprises a first synergistic compound and two, three, four, five, or six additional synergistic compounds.

[0101] In particular embodiments, the accord composition comprises at least one synergistic compound selected from the group consisting of amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, florol, linalool, citral, trans-2-cis-6-nonadien-l-ol, betaionone, damascene alpha, decalactone delta, damascenone total, damascene delta, decalactone delta, and combinations thereof. In further embodiments, the accord composition comprises at least one synergistic compound selected from the group consisting of amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, florol, linalool, citral, trans-2-cis-6- nonadien-l-ol, beta-ionone, damascene alpha, and combinations thereof. In particular embodiments, the accord composition comprises at least one synergistic compound selected from the group consisting of amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, florol, and combinations thereof. In particular embodiments, the accord composition comprises at least one synergistic compound selected from the group consisting of amyl cinnamic aldehyde, citronellol, geraniol, musk T, undecalactone G, florol, and combinations thereof.

[0102] In certain embodiments, when the accord composition comprises one synergistic compound, the synergistic compound is selected from the group consisting of geraniol, benzyl phenyl acetate, hexyl cinnamic aldehyde, 2-cyclohexylidene-2-phenylacetonitrile, phenyl ethyl alcohol, thymol, Z-dihydro citronellol, laurinal, undecalactone G, florol, alcohol C-12, alcohol C-8, aldehyde C-8, L-citronellal, musk T, nutmeg oil, and pinene beta. In certain embodiments, when the accord composition comprises one synergistic compound, the synergistic compound is selected from the group consisting of geraniol, benzyl phenyl acetate, hexyl cinnamic aldehyde, 2-cyclohexylidene-2-phenylacetonitrile, phenyl ethyl alcohol, thymol, Z-dihydro citronellol, undecalactone G, florol, alcohol C-12, alcohol C-8, aldehyde C-8, L-citronellal, musk T, nutmeg oil, and pinene beta. In certain embodiments, when the accord composition comprises one synergistic compound, the synergistic compound is selected from the group consisting of geraniol, benzyl phenyl acetate, hexyl cinnamic aldehyde, 2-cyclohexylidene-2- phenylacetonitrile, phenyl ethyl alcohol, thymol, Z-dihydro citronellol, laurinal, undecalactone G, florol, alcohol C-12, alcohol C-8, aldehyde C-8, L-citronellal, musk T, nutmeg oil, linalool,

[0103] ACTIVE 513686434.1 12 Attorney Docket No.: 071950.0475 and pinene beta. In certain embodiments, when the accord composition comprises one synergistic compound, the synergistic compound is selected from the group consisting of geraniol, benzyl phenyl acetate, hexyl cinnamic aldehyde, 2-cyclohexylidene-2- phenylacetonitrile, phenyl ethyl alcohol, thymol, Z-dihydro citronellol, undecalactone G, florol, alcohol C-12, alcohol C-8, aldehyde C-8, L-citronellal, musk T, nutmeg oil, linalool, and pinene beta.

[0104] In particular embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound, the first synergistic compound is selected from the group consisting of geraniol, benzyl phenyl acetate, hexyl cinnamic aldehyde, 2-cyclohexylidene-2-phenylacetonitrile, phenyl ethyl alcohol, thymol, Z-dihydro citronellol, laurinal, undecalactone G, florol, alcohol C-12, alcohol C-8, aldehyde C-8, L-citronellal, musk T, nutmeg oil, and pinene beta. In certain embodiments, when the accord composition comprises a first synergistic compound and at least one additional compound, the first synergistic compound is selected from the group consisting of benzyl phenyl acetate, hexyl cinnamic aldehyde, phenyl ethyl alcohol, thymol, alcohol C-12, alcohol C-8, aldehyde C-8, L- citronellal, geraniol, musk T, nutmeg oil, and pinene beta. In alternative embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound, the first synergistic compound is selected from the group consisting of Z-dihydro citronellol, laurinal, undecalactone gamma, and florol. In further embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound, the first synergistic compound is selected from the group consisting of citronellol, undecalactone gamma, and florol. In particular embodiments, when the accord composition comprises a first compound and at least one additional compound, the first synergistic compound is geraniol. In particular embodiments, when the accord composition comprises a first compound and at least one additional compound, the first synergistic compound is musk T.

[0105] In particular embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound, the at least one additional synergistic compound is selected from the group consisting of geraniol, benzyl phenyl acetate, hexyl cinnamic aldehyde, 2-cyclohexylidene-2-phenylacetonitrile, phenyl ethyl alcohol, thymol, laurinal, undecalactone G, alcohol C-12, alcohol C-8, L-citronellal, musk T, nutmeg oil, pinene beta, carvacrol, damascene alpha, capric acid, octalactone gamma, sandalwood, amyl cinnamic aldehyde, cinnamic aldehyde, cinnamic acid, damascenone total, damascene delta, ethyl caprate, ionone beta, ionone alpha, lilial, lauric acid, alcohol C-10, alcohol C-9,

[0106] ACTIVE 513686434.1 13 Attorney Docket No.: 071950.0475 aldehyde C-10, aldehyde C-9, aldehyde C-8, benzyl benzoate, canthoxal, citral, citron ellyl acetate, citronellyl nitrile, decalactone gamma, decen-l-ol, Z-dihydro citronellol, hedirosa, heptanoic acid, menthol, trans-2-cis-6-nonadien-l-ol, nonalactone delta, nonenal cis 6, origanum oil, perilla aldehyde, vetiverol ECO, caprylic acid, cinnamon bark oil, cinnamon leaf oil, cinnamyl acetate, dodecalactone delta, dodecalactone gamma, undecalactone gamma, decalactone delta, benzyl phenyl acetate, benzaldehyde, citronellol, laurinal, musk T, undecalactone G, florol, and linalool.

[0107] In certain embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound, the at least one additional synergistic compounds are amyl cinnamic aldehyde and undecalactone G. In alternative embodiments, the additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, and florol. In further embodiments, the additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T. In further embodiments, the at least one additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, citronellol, and musk T. In other embodiments, the additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, Citronellol, and musk T.

[0108] In particular embodiments, the accord composition comprises seven synergistic compounds selected from the group consisting of amyl cinnamic aldehyde, citronellol, florol, geraniol, laurinal, musk T, and undecalactone G. In alternative embodiments, the accord composition comprises six synergistic compounds selected from the group consisting of amyl cinnamic aldehyde, citronellol, florol, geraniol, musk T, and undecalactone G.

[0109] In certain embodiments, the accord composition comprises the first synergistic compound musk T and additional synergistic compounds amyl cinnamic aldehyde, undecalactone G, and florol. In certain embodiments, the accord composition comprises the first synergistic compound musk T and additional synergistic compounds amyl cinnamic aldehyde, citronellol, undecalactone G, and florol. In certain embodiments, the accord composition comprises the first synergistic compound geraniol and additional synergistic compounds amyl cinnamic aldehyde, citronellol, musk T, undecalactone G, and florol. In certain embodiments, the accord composition comprises the first synergistic compound geraniol and additional synergistic compounds amyl cinnamic aldehyde, musk T, undecalactone G, and florol.

[0110] In particular embodiments, the accord composition comprises more than one synergistic compound in an amount of from about 50% to about 99.9%, from about 65% to

[0111] ACTIVE 513686434.1 14 Attorney Docket No.: 071950.0475 about 99.5%, from about 80% to about 99%, from about 85% to about 98%, from about 90% to about 97%, or from about 94% to about 96% by weight of the accord composition. In alternative embodiments, the accord composition comprises synergistic compounds in an amount of from about 0.01% to about 50%, 0.05% to about 50%, from about 0.1 to about 50%, from about 0.5% to about 45%, from about 1.0% to about 25%, from about 5.0% to about 15%, or from about 5.0% to about 10% by weight of the accord composition.

[0112] In particular embodiments, when the accord composition comprises one synergistic compound, the accord composition comprises one synergistic compound in an amount of from about 50% to about 99.9%, from about 65% to about 99.5%, from about 80% to about 99%, from about 85% to about 98%, from about 90% to about 97%, or from about 94% to about 96% by weight of the accord composition. In alternative embodiments, the accord composition comprises one synergistic compound in an amount of from about 0.01% to about 50%, 0.05% to about 50%, from about 0.1 to about 50%, from about 0.5% to about 45%, from about 1.0 to about 25%, from about 5.0 to about 15%, or from about 5.0 to about 10% by weight of the accord composition.

[0113] In certain embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound, the accord composition comprises a first synergistic compound in an amount of from about 0.1% to about 75%, from about 1% to about 75%, from about 5% to about 75%, from about 10% to about 75%, from about 25% to about 75%, from about 30% to about 70%, from about 35% to about 50%, from about 50% to about 70%, or from about 38% to about 48% by weight of the accord composition. In alternative embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound, the accord composition comprises a first synergistic compound in an amount of from about 0.1% to about 5%, from about 0.5% to about 4%, or from about 1% to about 3.5% by weight of the accord composition. In further embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound, the accord composition comprises a first synergistic compound in an amount of from about 20% to about 75%, from about 0.5% to about 4%, or from about 1% to about 3.5% by weight of the accord composition.

[0114] In particular embodiments, when the accord composition comprises a first synergistic compound and at least one additional synergistic compound the accord composition comprises at least one additional synergistic compound in an amount of from about 25% to about 70%, from about 35% to about 65%, from about 40% to about 50% or from about 48% to about 58% by weight of the accord composition. In alternative embodiments, when the

[0115] ACTIVE 513686434.1 15 Attorney Docket No.: 071950.0475 accord composition comprises a first synergistic compound and at least one additional synergistic compound the accord composition comprises at least one additional synergistic compound in an amount of from about 80% to about 99%, from about 85% to about 98%, or from about 90% to about 96% by weight of the accord composition.

[0116] In particular embodiments, the accord composition comprises a first synergistic compound in an amount of from about 38% to about 48% and at least one additional synergistic compound in an amount of from about 48% to about 58% by weight of the accord composition.

[0117] 3,3 Accord Compositions

[0118] The accord compositions of the present disclosure comprise hinokitiol and at least one synergistic compound. The accord compositions of the present disclosure comprise hinokitiol, a first synergistic compound, and at least one additional synergistic compound. In particular embodiments, the accord composition comprises hinokitiol, a first synergistic compound, and at least two additional synergistic compounds. In certain embodiments, the accord composition comprises two, three, four, five, or six additional synergistic compounds. In alternative embodiments, the accord composition comprises at least one, two, three, four, five, six, or seven synergistic compounds.

[0119] In certain embodiments, the accord composition comprises hinokitiol in amount of from about 0.1% to about 20%, from about 1% to about 15%, from about 2.5% to about 10%, from about 5% to about 15%, from about 6% to about 15%, from about 6.5% to about 8%, from about 4% to about 7%, from about 4.5% to about 6.5% by weight of the accord composition and at least one synergistic compound in an amount of from about 50% to about 99.9%, from about 65% to about 99.5%, from about 80% to 99%, from about 85% to about 98%, from about 90% to about 97%, or from about 94% to about 96% by weight of the accord composition. In alternative embodiments, the accord composition comprises hinokitiol in amount of from about 0. 1% to about 20%, from about 1% to about 15 %, from about 2.5% to about 10%, from about 5% to about 15%, from about 6% to about 15%, from about 6.5% to about 8%, from about 4% to about 7%, from about 4.5% to about 6.5% by weight of the accord composition and synergistic compounds in an amount of from about 0.01% to about 95%, 0.05% to about 60%, from about 0.1 to about 50% or from about 0.5% to about 45% by weight of the accord composition.

[0120] In further embodiments, the accord composition comprises hinokitiol in amount of from about 0.1% to about 20%, from about 0.5% to about 15 %, from about 1.0% to about 10%, or from about 2% to about 5.5% and synergistic compounds in an amount of from about

[0121] ACTIVE 513686434.1 16 Attorney Docket No.: 071950.0475

[0122] 50% to about 99.9%, from about 65% to about 99.5%, from about 80% to 99%, from about 85% to about 98%, from about 90% to about 97%, or from about 94% to about 96% by weight of the accord composition

[0123] In particular embodiments, the accord composition comprises hinokitiol in amount of from about 0.1 to about 20%, from about 1% to about 15 %, from about 2.5% to about 10 %, from about 4% to about 7%, or from about 4.5% to about 6.5% by weight of the accord composition, a first synergistic compound in an amount of from about 25% to about 60%, from about 30% to about 55%, from about 35% to about 50%, or from about 38% to about 48% by weight of the accord composition, and additional synergistic compounds in an amount of from about 25% to about 70%, from about 40% to about 65%, from about 45% to about 50% or from about 48% to about 58% by weight of the accord composition.

[0124] In certain embodiments, the accord composition comprises hinokitiol and at least one synergistic compound selected from the group consisting of hinokitiol, amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, florol, linalool, and combinations thereof.

[0125] In certain embodiments, the accord composition comprises hinokitiol, the first synergistic compound geraniol, and additional synergistic compounds selected from the group consisting of amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T.

[0126] In particular embodiments, the accord composition comprises hinokitiol, a first synergistic compound and two additional synergistic compounds. In certain embodiments, the accord composition comprises hinokitiol, the first synergistic compound geraniol, and the two additional synergistic compounds amyl cinnamic aldehyde and undecalactone G.

[0127] In certain embodiments, the accord composition comprises hinokitiol, a first synergistic compound, and three additional synergistic compounds. In particular embodiments, the accord composition comprises hinokitiol, the first synergistic compound geraniol, and the three additional synergistic compounds amyl cinnamic aldehyde, undecalactone G, and florol.

[0128] In particular embodiments, the accord composition comprises hinokitiol, a first synergistic compound, and six additional synergistic compounds. In certain embodiments, the accord composition comprises hinokitiol, the first synergistic compound geraniol, and the six additional synergistic compounds amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T. In alternative embodiments, the accord composition comprises hinokitiol, the first synergistic compound geraniol, and the five additional

[0129] ACTIVE 513686434.1 17 Attorney Docket No.: 071950.0475 synergistic compounds amyl cinnamic aldehyde, undecalactone G, florol, citronellol, and musk T.

[0130] In alternative embodiments, the accord composition comprises hinokitiol and seven synergistic compounds. In particular embodiments, the accord composition comprises hinokitiol and geraniol, amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T.

[0131] In further embodiments, the accord composition comprises hinokitiol and six synergistic compounds. In particular embodiments, the accord composition comprises hinokitiol and geraniol, amyl cinnamic aldehyde, undecalactone G, florol, citronellol, and musk T.

[0132] In certain embodiments, the accord composition comprises hinokitiol, the first synergistic compound musk T and additional synergistic compounds amyl cinnamic aldehyde, undecalactone G, and florol. In certain embodiments, the accord composition comprises hinokitiol, the first synergistic compound musk T and additional synergistic compounds amyl cinnamic aldehyde, citronellol, undecalactone G, and florol. In certain embodiments, the accord composition comprises hinokitiol, the first synergistic compound musk T and additional synergistic compounds amyl cinnamic aldehyde, citronellol, undecalactone G, geraniol, and florol. In certain embodiments, the accord composition comprises hinokitiol, the first synergistic compound geraniol, additional synergistic compounds amyl cinnamic aldehyde, citronellol, musk T, undecalactone G, and florol. In certain embodiments, the accord composition comprises hinokitiol, the first synergistic compound geraniol, and additional synergistic compounds amyl cinnamic aldehyde, musk T, undecalactone G, and florol.

[0133] In particular embodiments, the accord composition comprises hinokitiol and at least one synergistic compound selected from the group consisting of amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, florol, linalool, citral, trans-2-cis-6- nonadien-l-ol, beta-ionone, damascene alpha, decalactone delta, damascenone total, damascene delta, decalactone delta, and combinations thereof. In further embodiments, the accord composition comprises hinokitiol and at least one synergistic compound selected from the group consisting of amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, florol, linalool, citral, trans-2-cis-6-nonadien-l-ol, beta-ionone, damascene alpha, and combinations thereof. In particular embodiments, the accord composition comprises hinokitiol and at least one synergistic compound selected from the group consisting of amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, florol, and combinations thereof.

[0134] ACTIVE 513686434.1 18 Attorney Docket No.: 071950.0475

[0135] In particular embodiments, the accord composition comprises hinokitiol and the synergistic compounds amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, florol, and combinations thereof. In particular embodiments, the accord composition comprises hinokitiol and the synergistic compounds amyl cinnamic aldehyde, citronellol, geraniol, musk T, undecalactone G, florol, and combinations thereof.

[0136] In alternative embodiments, the accord composition comprises hinokitiol and the synergistic compounds amyl cinnamic aldehyde, citronellol, geraniol, musk T, undecalactone G, florol, citral, delta decalactone, damascenone, alpha damascene, delta damascene, betaionone, trans-2-cis-6-nonadien-l-ol, and linalool. In further embodiments, the accord composition comprises hinokitiol and the synergistic compounds amyl cinnamic aldehyde, citronellol, geraniol, musk T, undecalactone G, florol, and linalool.

[0137] In certain embodiments, the accord composition further comprises a solvent. The solvent is any suitable solvent known in the art, as disclosed herein.

[0138] In certain embodiments, the accord compositions exhibit anti-bacterial and / or antifungal activity. In particular embodiments, the accord compositions exhibit anti-bacterial and / or anti-fungal activity, discussed in more detail herein.

[0139] 3,4 Fragrance Compositions

[0140] Fragrance compositions can be formulated with one or more accord compositions of the present disclosure. The fragrance compositions comprise one or more accord composition and at least one additional fragrance compound or one or more accord composition, at least one additional fragrance compound, and at least one solvent.

[0141] The additional fragrance compound can be any suitable fragrance compound known in the art. These additional fragrance compounds can be selected from various aroma groups known in the art. The aroma groups can be, but are not limited to, one or more animalic compound(s), one or more anise compound(s), one or more aldehydic compound(s), one or more balsamic compound(s), one or more citrus compound(s), one or more floral compound(s), one or more fruity compound(s), one or more gourmand compound(s), one or more green compound(s), one or more marine compound(s), one or more mossy compound(s), one or more musk compound(s), one or more mint compound(s), one or more pine compound(s), one or more powdery compound(s), one or more spicy compound(s), one or more woody compound(s), one or more herbal compound(s), one or more hay compound(s), and / or one or more camphoraceous compound(s), and combinations thereof.

[0142] ACTIVE 513686434.1 19 Attorney Docket No.: 071950.0475

[0143] Non-limiting examples of aldehydic compounds include l-methyl-4-(4-methyl-3- pentenyl)cyclohex-3-ene-l-carboxaldehyde, aldehyde C-l l undecylenic, 2,6,10- trimethylundec-9-enal, aldehyde C-10, aldehyde C-8, myrac aldehyde, acetaldehyde C-9, aldehyde C-12, aldehyde supra, cyclomyral trans-2-decenal, trans-4-decenal, cis-4-decenal, 9- decenal, trans-2-dodecenal, trans-4-dodecenal, undecylenic aldehyde, 2,6-dimethyl-5- heptenal, pinoacetaldehyde, 2-methylundecanal, trans-2-dodecenal, and l-methyl-4-(4- methylpentyl)cyclohex-3-ene-l-carbaldehyde.

[0144] Non-limiting examples of animalic compounds include musk methyl propionate, 5- cyclohexadecen-l-one, 17-oxacycloheptadec-6-en-l-one, 2,5,5-trimethyl-l,3,4,4a,6,7- hexahydronaphthalen-2-ol, 2-methyl-5-(5,5,6-trimethylbicyclo[2.2.1]hept-2- yl)cyclohexanone, civet, p-cresol, cresyl methyl ether, indole, isobutyl quinoline, sulfurol, 3- methyl-5-cyclopentadecen-l-one and skatole.

[0145] Non-limiting examples of anise compounds include 1 -methoxy -4- [(E)-prop-l- enyl]benzene, l-(cyclopropylmethyl)-4-methoxybenzene, and anise star.

[0146] Non-limiting examples of balsamic compounds include benzoin, phenyl propyl alcohol, methyl cinnamate, 2-hydroxybenzoic acid 2-(l -methyl ethoxy) ethyl ester, cyclohexyl salicylate, orbitone, amyris oil, and 3,7,1 l-trimethyldodeca-l,6,10-trien-3-ol.

[0147] Non-limiting examples of camphoraceous compounds include borneol, bornyl isobutyrate, camphor, fenchone, menthol (e.g., menthol L), and / or rosemary oil.

[0148] Non-limiting examples of citrus compounds include d-limonene, citral, linalyl acetate, citronellyl nitrile, dihydromyrcenol, orange oil, limediene, lime oil terpenes, limonene thiol, terpinyl acetate, citronellal, lime oil, 2,4,6-trimethyl-4-phenyl-l,3-dioxane, dimethyl anthranilate, trans-2-dodcanal, lemongrass oil, delta-3 -carene, L-citronellol, decanal, DH-L- citronellol, myrcenol, limonene, nootkatone, sinensal, bergamot oil, grapefruit oil, lemon oil, lime oil, mandarin oil, tridecene-2 -nitrile, grapefruit menthane, l,l-dimethoxy-2,2,5-trimethyl- 4-hexene, and yuzu core base.

[0149] Non-limiting examples of floral compounds include hexyl cinnamic aldehyde, 1,3- benzodioxole-5-carbaldehyde, linalool, 4-methyl-2-(2-methylpropyl)oxan-4-ol, (2E)-3,7- dimethylocta-2,6-dien-l-ol, 3-(4-tert-butylphenyl)propanal, diphenyl oxide, (6E)-3,7- dimethylnona-l,6-dien-3-ol, 3-(l,3-benzodioxol-5-yl)-2-methylpropanal, citronellol, 2,4- dimethyl-4,4a,5,9b-tetrahydroindeno[l,2-d][l,3]dioxine, benzyl acetate, 4-(2,6,6- trimethylcyclohexen-l-yl)but-3-en-2-one, methyl 3-oxo-2-pentylcyclopentaneacetate, 2- methyl-3-(4-propan-2-ylphenyl)propanal, phenyl ethyl alcohol, (3-butyl-5-methyloxan-4-yl) acetate, [(2E)-3,7-dimethylocta-2, 6-dienyl] acetate, methyl 3-oxo-2-

[0150] ACTIVE 513686434.1 20 Attorney Docket No.: 071950.0475 pentylcyclopentaneacetate, tetrahydrolinalool, L-cis-rose oxide, 3 -(3 -propan-2 - ylphenyl)butanal, pyranol, phenyl ethyl formate, 7-hydroxy-3,7-dimethyloctanal, (4-propan-2- ylcyclohexyl)methanol, (E)-3-methyl-4-(2,6,6-trimethyl-l-cyclohex-2-enyl)but-3-en-2-one, 2 -phenyl propyl alcohol, 2,2,5-trimethyl-5-pentylcyclopentan-l-one, phenoxy ethyl isobutyrate, ethyl linalyl acetate, isobutyl salicylate, methyl benzoate, citronellyl acetate, 2- heptylcyclopentan-l-one, lactone of dihydrojasmone, cis-jasmone, (3-pentyloxan-4-yl) acetate, dimethyl octanol, nerolione, 3-(4-tert-butylphenyl)propanal, phenylethylacetate, alpha-amyl cinnamyl aldehyde, 4-methyl-2-(2-methylpropyl)oxan-4-ol, 2-cyclohexylidene-2- phenylacetonitrile, phenoxanol, (E)-4-(2,6,6-trimethyl-l-cyclohex-2-enyl)but-3-en-2-one, rose oxide, 4-(2,6,6-trimethyl-l-cyclohex-2-enyl)pentanal, (2Z)-3,7-dimethylocta-2,6-dien-l- ol, 2,2-dimethyl-3-(3-methylphenyl)propan-l-ol, methyl naphthyl ketone, methyl 2- aminobenzoate, (E)-3-methyl-4-(2,6,6-trimethyl-l-cyclohex-2-enyl)but-3-en-2-one, myrcenol, 9-decen-l-ol, l-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanone, 3-(4-isobutyl- phenyl)-2-methyl-propionaldehyde, hexyl cinnamaldehyde, hexyl salicylate, indole, dimethyl benzyl carbinol, famesal, 1-dihydrofarnesal, 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-l- carbaldehyde, laurinal, lilial, methyl dihydrojasomante, methoxymelonal, methyl benzoate, 1- (4-isopropyl-cyclohexyl) ethanol, nerol, l-(3-methyl-benzofuran-2-yl)-ethanone, neryl acetate, orantha, L., 2-pentyl cyclopentanone, yara, geranium oil, rose oil, lavender oil, floralozone, 4- (Octahydro-4,7-methano-5H-inden-5, 3-(3-isopropylphenyl)butanal, dihydro-4-methyl-5- pentyl furan-2(3H)-one, gardenia pentyl acetate, gardenia acetal, N-l-(2,6,6-trimethyl-l- cyclohex-2-enyl)pent-l-en-3-one, 2-Cyclohexylidene-2-phenylacetonitrile, and ylang oil.

[0151] Non-limiting examples of fruity compounds include ethyl 2-methyl butyrate, (2 -tertbutylcyclohexyl) acetate, ethyl methylphenylglycidate, raspberry ketone, delta-dodecalactone, dimethyl benzyl carbinyl butyrate, methyl dioxolan, gamma-undecalactone, hedione, benzyl propionate, gamma-decalactone, isoamyl isovalerate, ethyl isovalerate, hexyl isobutyrate, diethyl malonate, dimethyl benzyl carbinyl acetate, ethyl (lR,6S)-2,2,6-trimethylcyclohexane-

[0152] 1 -carboxylate, 2,6-dimethylhept-5-enal, oxane 50% in TEC, allyl caproate, ethyl heptoate, ethyl butyrate, 3-tricyclo[5.2. E02,6]dec-3-enyl acetate, cis-6-nonenal, ethyl acetoacetate, cassis base, 3-methylbut-2-enyl acetate, damascenone, 6-(pent-3-en-l-yl)tetrahydro-2H-pyran-

[0153] 2-one, cis-3-hexenyl butyrate, beta-damascone, 4-(l,3-benzodioxol-5-yl)butan-2-one, allyl cyclohexyl propionate, alpha-damascone, dimethyl benzyl carbinol acetate, dimethyl sulfide, ethyl acetate, ethyl caproate, ethyl decadienoate, ethyl tri cyclo [5.2. E02.6] decan-2 carboxylate, methyl (2-((4S)-4-methyl-2-methylenecyclohexyl)propan-2-yl)sulfane, p- mentha-8-thiol-3-one, 3, 5, 5 -trimethylhexyl acetate, galbascone, manzanate, 8-methyl-l-

[0154] ACTIVE 513686434.1 21 Attorney Docket No.: 071950.0475 oxaspiro[4.5]decan-2-one, veltol plus, green acetate, ethyl 2,2,6- trimethylcyclohexanecarboxylateand nopyl acetate.

[0155] Non-limiting examples of gourmand compounds include ethyl vanillin, gammadodecalactone, butyl butyryl lactate, benzaldehyde, isobutyl lignate, acetyl methyl carbinol, cyclotene, 3,4-diethyl-2,5-dimethylcyclohex-2-en-l-one, furaneol, tolylaldehyde, angelica lactone-alpha, caprylic acid, ethyl fraison, guaiacol, maple furanone, 2-acetyl pyrazine, 2,5- dimethyl pyrazine, octano-l,5-lactone, gamma-nonalactone, and vanillin.

[0156] Non-limiting examples of green compounds include 1 -phenylethyl acetate, 2,4- dimethylcyclohex-3-ene-l-carbaldehyde, trans-2-hexenal, trans-2-hexanol, cis-2-hexen-l-ol, undecavertol, phenyl acetaldehyde, octahydro-5 -meth oxy -4, 7-methano-l H-indene-2- carboxaldehyde, 2,4,6-trimethylcyclohex-3-ene-l-carbaldehyde, cis-3-hexenyl acetate, [(4Z)- l-cyclooct-4-enyl] methyl carbonate, allyl amyl glycolate, phenyl acetaldehyde dimethyl acetal, cis-3-hexen-l-ol, N-(5-methylheptan-3-ylidene)hydroxylamine, cis-3-hexenyl salicylate, l-(5,5-dimethyl-l-cyclohexenyl)pent-4-en-l-one), cis-3-hexenyl benzoate, phenyl acetaldehyde, methyl octine carbonate, cis-3-hexenyl isobutyrate, [(Z)-hex-3-enyl] methyl carbonate, methyl heptane carbonateviolet leaf, cyclogalbanate, l-(5,5-dimethyl-l- cyclohexen-l-yl)-4-penten-l-one, galbanolene, galbanum, 2-m ethoxy -2-methylheptane, neofolione, 2,6-nonadienal, (2R,4S)-2-methyl-4-propyl-l,3-oxathiane, galbex, scentenal, styrallyl acetate, eugenol, methyl 2-octynoate, 4-methyl-3-decen-5-ol, and vionil.

[0157] Non-limiting examples of hay compounds include acetanisole, gamma-heptalactone, acetanisole, gamma-octalactone, and 2,6-dimethylheptan-2-ol.

[0158] Non-limiting examples of herbal compounds include 2,2,6-trimethyl-alpha- propylcyclohexanepropanol, gamma-hexalacotone, cyclohexyl lactone, eucalyptus oil, amyl salicylate, lavandin oil, eucalpytol, rosemary oil, carrot seed oil, 3-(4-methoxyphenyl)-2- methylpropanal, anethol, bamboo ketone, carvacrol, carvone-L, clary sage natural oil, p- cymene, Daikon Ether, 2,6-dimethylheptan-2-ol, menthol, methyl salicylate, thymol, natural basil oil, natural eucalyptus oil, eucalyptol, sweet natural fennel oil, cypressan, and natural cedar leaf oil.

[0159] Non-limiting examples of marine compounds include 3-(4-ethylphenyl)-2,2- dimethylpropanal, 4-tert-butylphenylacetonitrile, 4-[(3E)-4,8-dimethylnona-3,7- dienyl]pyridine, myrac aldehyde, pino acetaldehyde, 7- methyl-2-H-l,5-Benzodioxepin- 3(4H)-one, 2-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethyl acetate, and ultrazure.

[0160] Non-limiting examples of mossy compounds include hinokitiol, isobutyl quinolone, and isopropyl quinolone.

[0161] ACTIVE 513686434.1 22 Attorney Docket No.: 071950.0475

[0162] Non-limiting examples of musk compounds include 1,4-dioxacycloheptadecane- 5, 17-dione and (5E)-3-methylcyclopentadec-5-en-l-one, 5-cyclohexadecen-l-one, 17- oxacycloheptadec-6-en- 1 -one, 2, 2, 6-trimethyl-alpha-propyl cyclohexanepropanol, 16- oxacyclohexadecan-l-one, galaxolide, ((12E)-l-oxacyclohexadec-12-en-2-one, [2-[l-(3,3- dimethylcyclohexyl)ethoxy]-2-methylpropyl]propanoate, 3 -methylcyclopentadecan- 1 -one, 1- (l,l,2,6-tetramethyl-3-propan-2-yl-2,3-dihydroinden-5-yl)ethanone, and 1 -(3, 5, 5, 6, 8, 8- hexamethyl-6,7-dihydronaphthalen-2-yl)ethanone.

[0163] Non-limiting examples of mint compounds include L-menthol, 2-butan-2- ylcyclohexan-l-one, commint oil, peppermint oil, spearmint oil, and L-carbone.

[0164] Non-limiting examples of powdery compounds include heliotropine, coumarin, and / or whiskey lactone.

[0165] Non-limiting examples of pine compounds include isobornyl acetate, camphor, cypress oil, borneol, pine oil, fir needle Canadian, juniper berry, alpha-terpineol, 1 -bornyl acetate, camphene, camphor gum powder, dihydroterpineol, and beta-pinene.

[0166] Non-limiting examples of spicy compounds include ceylon cinnamon leaf oil, cinnamyl acetate, clove leaf oil, clove bud oil, elemi oil, valspice, acetyl eugenol, ginger root, isoeugenol, acetyl isoeugenol, delta-caryophellene, cardamon oil, cinnamaldehyde, cuminaldehyde, perilla aldehyde, cardamom oil, clove oil, ginger extract, ginger oil, 2,3,3- trimethylindan-l-one, and black pepper extract.

[0167] Non-limiting examples of woody and / or amber compounds include (E)-2-ethyl-4- (2, 2, 3 -trimethyl- 1-cy cl opent-3 -enyl)but-2-en-l-ol, 4-(l-ethoxyethenyl)-3,3,5,5- tetramethylcyclohexan-l-one, patchouli oil, (lS,2R,5S,7R,8R)-2,6,6,8- tetramethyltricyclo[5.3.1.01,5]undecan-8-ol, l-(2,2,6-trimethylcyclohexyl)hexan-3-ol, ethoxymethoxycyclododecane, l-(2-tert-butylcyclohexyl)oxybutan-2-ol, 3-methyl-5-(2,2,3- trimethyl-1 -cyclopent-3 -enyl)pentan-2-ol, cedarwood oil, cedrol methyl ether, 1- [(lR,2R,5S,7R)-2,6,6,8-tetramethyl-9-tricyclo[5.3.1.01,5]undec-8-enyl]ethanone, [(1R,2S)-1- methyl-2-[[(lR,3S,5S)-l,2,2-trimethyl-3- bicyclo[3.1.0]hexanyl]methyl]cyclopropyl]methanol, (E)-2-methyl-4-(2,2,3-trimethyl-l- cyclopent-3-enyl)but-2-en-l-ol, l,l,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, cedanol, 3-Methyl-5-(2,2,3-trimethyl-3-cyclopenten-l-yl)-4-penten-2-ol, (R,E)-2-Methyl-4- (2,2,3 -trimethylcy cl opent-3 -enyl) but-2-en-l-ol, cedramber (cedryl methyl ether), DH-ionone beta, 5-butan-2-yl-2-(2,4-dimethyl-l-cyclohex-3-enyl)-5-methyl-l,3-dioxane, 2,4-Dimethyl- 2-( 1,1, 4, 4-tetramethyltetralin-6-yl)- 1,3 -di oxolane, 2-ethyl-4-[(lR)-2,2,3-trimethyl-3- cyclopenten-l-yl]-(2E)-buten-l-ol, polysantol, rhubofix, sandalwood, 7-Methyl-2,4-dihydro-

[0168] ACTIVE 513686434.1 23 Attorney Docket No.: 071950.0475 musk indenofuran, labdanum, hindinol, oakmoss, sandalore, vertenex, dextramber, ambroxan, linaly[l-Methyl-2-[(l,2,2-trimethylbicyclo[3.1.0]hex-3-yl)methyl]cyclopropyl]methanol, decahydro-2,2,6,6,7,8,8-heptamethyl indenofuran, (4aR,5R,7aS,9R)-Octahydro-2,2,5,8,8,9a- hexamethyl-4H-4a,9-methanozuleno[5,6-d]- 1,3 -di oxole, olibanum oil, patchouli hexanol, clearwood, and 2,2,6-trimethyl-alpha-propylcyclohexanepropanol.

[0169] In certain embodiments, the solvents can include, but are not limited to, dipropylene glycol, propylene glycol, dieth-phthalate (DEP), diisononyl phthalate (DINP), benzyl benzoate, benzyl alcohol, iso propyl myristate (IPM), isopropyl palmitate (IPP / Deltyl Prime), butyl stearate, dioctyl adipate, tri ethyl citrate, methyl hydrogenated rosinate (CAS No. 8050-15-5), terpenes (e.g., Glidsol 100), paraffinic naphthenic solvent (e.g., LPA-170 Solvent), isoalkanes (e.g., Soltrol 170 Isoparaffin), isoparaffins, isooctadecanol (e.g., Tego Alkanol 66), phenoxyethanol, diethylene glycol monoethyl ether (Carbitol low gravity), glycol ether (Methyl Carbitol), Dipropylene Glycol Methyl Ether (e.g., Dowanol DPM), Dipropylene Glycol Methyl Ether Acetate (e.g., Dowanol DPMA), Propylene glycol methyl ether (e.g., Dowanol PM Glycol Ether), Tripropylene Glycol Methyl Ether, Diisoheptyl Phthalate (e.g., Jayflex® 77 available from Exxon), deionized or distilled water, specially denatured ethyl alcohol (e.g., SDA 40B), Dimethyl Adipate / Dimethyl Glutarate (e.g., DBE®-LVP Esters available from FLEXISOLV®), Racemic mixture (+ / -)-2,2-dimethyl-4-hydroxymethyl-l,3- di oxolane (e.g., Augo Clean Multi Solvent), Alcohol 40B Anhydrous 200 Proof, alcohol SDA 40B 190 Proof, Triacetin, 3 -Methoxy-3 -methyl- 1 -butanol (Solfit), Benzyl Laurate, Tripropylene Glycol Methyl Ether (e.g., Dowanol TPM), Dipropylene glycol n-butyl ether (e.g., Dowanol DPNB), Dimethyl siloxane, trimethylsiloxy-terminated (e.g., Dowanol Corning 200 Fluid), Caprylic / Capric Triglycerides (e.g., Neobee M-5), propylene glycol and glyceryl oleate (e.g., Arlacel 186), Uniceth-IC20L (e.g., Arlasolve 200 L), propanediol, 1, 3, Butyl Cellosolve, Hexylene glycol, Glycerine, N Methyl Stearate, Isopropyl alcohol, 2-Methyl-l,3- propanediol (e.g., MP Diol Glycol), Diethyl Citrate, Triethyl Acetyl Citrate, Isopentyldiacetate (IPD-AC), Dimethyl 2-methylpentanedioate (e.g., Rhodiasolv Iris), medium chain triglycerides (MTC), terpene hydrocarbons (e.g., Dipentene 5100), DL-limonene (e.g., Dipentene 122), 3, 5, 5 -trimethylhexyl acetate, Diethyl Malonate, Limonene (e.g., Unitene D), cyclohexyl acetate, para-tertiary-butyl (e.g., Vertenex), Ethyl Acetate, and Diethyl Succinate.

[0170] In particular embodiments, at least one accord composition is included in a fragrance composition in an amount of from about 1% to about 30%, from about 3% to about 25%, from about 5% to about 20%, from about 10% to about 15%, or from about 10% to about 20% by weight of the fragrance composition. In alternative embodiments, at least one accord

[0171] ACTIVE 513686434.1 24 Attorney Docket No.: 071950.0475 composition is included in a fragrance composition in an amount of from about 30% to about 90%, from about 40% to about 80%, from about 50% to about 75%, from about 50% to about 60%, or from about 60% to about 75% by weight of the fragrance composition.

[0172] In certain embodiments, at least one additional fragrance compound is included in the fragrance composition in amount of from about 10% to about 70%, from about 20% to about 60%, from about 20% to about 40%, from about 40% to about 50%, or from 25% to about 50% by weight of the fragrance composition.

[0173] In particular embodiments, at least one solvent is included in a fragrance composition in an amount of from about 0.5% to about 20%, from about 1% to about 15%, or from about 5% to about 10% by weight of the fragrance composition.

[0174] In particular embodiments, the fragrance composition comprises from about from about 50% to about 60% of at least one accord composition, from about 40% to about 50% of at least one additional fragrance compound, and from about 5% to about 10% of a solvent. In particular embodiments, the fragrance composition comprises from about from about 60% to about 75% of at least one accord composition, from about 20% to about 40% of at least one additional fragrance compound and from about 5% to about 10% of a solvent.

[0175] The fragrance composition includes at least one accord composition. In certain embodiments, the fragrance composition includes one accord composition, as described above in Section 3.3. In alternative embodiments, the fragrance composition includes two accord compositions. When the fragrance compositions includes two accord compositions, the first accord composition is an accord composition as described above in Section 3.3 and the second accord composition is any suitable accord composition known in the art.

[0176] In particular embodiments, the second accord composition comprises additional synergistic compounds. The additional synergistic compounds are selected from the group consisting of delta decalactone, damascenone total, delta damescenone, beta-ionone, citral, trans-2-cis-6-nonadien-l-ol, and combinations thereof. In alternative embodiments, the additional synergistic compounds are selected from the group consisting of delta decalactone, damascenone total, delta damescenone, beta-ionone, citral, trans-2-cis-6-nonadien-l-ol, linalool, and combinations thereof.

[0177] When the fragrance composition comprises a first accord composition as described in Section 3.3 and a second accord composition comprising additional synergistic compounds, the first accord composition is present in an amount of from about 1% to about 30%, from about 3% to about 25%, or from about 5% to about 20% by weight of the fragrance composition and the second accord composition is present in an amount of from about 0.1% to about 10%,

[0178] ACTIVE 513686434.1 25 Attorney Docket No.: 071950.0475 from about 0.5% to about 5%, or from about 1% to about 3.5% by weight of the fragrance composition.

[0179] The fragrance composition can additionally comprise at least one compound which synergizes hinokitiol to M. restricta. In particular embodiments, the at least one compound which synergizes hinokitiol to M. restricta is linalool.

[0180] When the fragrance composition comprises a first accord composition as described in Section 3, a second accord composition comprising additional synergistic compounds, and at least one compound which synergizes hinokitiol to restricta, the first accord composition is present in an amount of from about 1% to about 30%, from about 3% to about 25%, or from about 5% to about 20% by weight of the fragrance composition and the second accord composition is present in an amount of from about 0.1% to about 10%, from about 0.5% to about 5%, or from about 1% to about 3.5% by weight of the fragrance composition, and the at least one compound which synergizes hinokitiol toM. restricta is present in an amount of from about 0.1% to about 10%, from about 0.5% to about 8%, or from about 0.75% to about 6.5% by weight of the fragrance composition.

[0181] The ratio of the first accord composition to the second accord composition is from about 50: 1 to about 1 : 1, from about 25: 1 to about 1 :1, or from about 15: 1 to about 1 : 1. In certain embodiments, the ratio of the first accord composition to the second accord composition is about 9: 1.

[0182] 4. Consumer Products

[0183] The accord compositions of the present disclosure can be formulated as part of a consumer product. Alternatively, a consumer product can be formulated with a fragrance composition.

[0184] Any suitable consumer product can be used. In certain embodiments, the consumer product is a hair care product.

[0185] In certain embodiments, the consumer products of the present disclosure can be, but are not limited to, hair care products including shampoos, conditioners, dry shampoos, hair masks, hair oils, hair serums, hair wax, hair pomade, hair gel, hair cream, hair creme, hair clay, hair powders, hair mousse, hair lotion, hair musk, hair texturizer, heat protectant spray, sea salt spray, scalp lotion, and other suitable hair care products. In particular embodiments, the consumer product is a shampoo.

[0186] ACTIVE 513686434.1 26 Attorney Docket No.: 071950.0475

[0187] In certain embodiments, the disclosed subject matter provides for the use of the accord compositions described herein for the use in a consumer product as described herein. In particular embodiments, the accord compositions are formulated as a part of a consumer product to improve the scalp microbiome.

[0188] In particular embodiments, the accord compositions are included in a consumer product in an amount of from about 0.01% to about 10%, from about 0.1% to about 5%, from about 0.25% to about 2% or from about 0.5% to about 1.5%, or from about 0.75% to about 1.25%, by weight of the consumer product. In certain embodiments, the accord compositions are included in a shampoo in an amount of from about 0.1% to about 5%, from about 0.25% to about 2% or from about 0.5% to about 1.5%, or from about 0.75% to about 1.25%, by weight of the shampoo.

[0189] In particular embodiments, the fragrance compositions are included in a consumer product in an amount of from about 0.01% to about 10%, from about 0.1% to about 5%, from about 0.25% to about 2%, from about 0.3% to about 1%, from about 1% to about 2%, or from about 0.75% to about 1.25% by weight of the consumer product. In certain embodiments, the fragrance compositions are included in a shampoo in an amount of from about 0.1% to about 5%, from about 0. .01% to about 10%, from about 0.1% to about 5%, from about 0.25% to about 2%, from about 0.3% to about 1%, from about 1% to about 2%, or from about 0.75% to about 1.25% by weight of the shampoo.

[0190] In particular embodiments, a consumer product is formulated with an accord composition comprising hinokitiol and at least one synergistic compound. In certain embodiments, a consumer product is formulated with an accord composition comprising hinokitiol and at least one synergistic compound, and at least one additional compound.

[0191] In particular embodiments, consumer product is formulated with a fragrance composition comprising an accord composition comprising hinokitiol and at least one synergistic compound. In particular embodiments, consumer product is formulated with a fragrance composition comprising an accord composition comprising hinokitiol and the first synergistic compounds geraniol and the additional synergistic compounds amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T.

[0192] In certain embodiments, the consumer product comprises additional synergistic compounds selected from the group consisting of delta-decalactone, damascenone total, delta- damescenone, beta-ionone, citral, trans-2-cis-6-nonadien-l-ol, and combinations thereof. In certain embodiments, the consumer product further comprises at least one compound which synergizes hinokitiol to M. restricta, where the compound is linalool.

[0193] ACTIVE 513686434.1 27 Attorney Docket No.: 071950.0475

[0194] The accord compositions provided herein can be admixed with any suitable fragrance, base, solvent, and combination thereof to form a hair care composition for use in a consumer product. In particular embodiments, an accord composition is admixed with a consumer product base to form a consumer product. In alternative embodiments, a fragrance composition is admixed with a consumer product base to form a consumer product.

[0195] In particular embodiments, the hair care composition comprises one or more bases, solvents, and combinations thereof. Any suitable base, solvent, or excipient can be used.

[0196] In certain embodiments, bases can include, but are not limited to, essential oils, lactones, aldehydes, alcohols, ketones, nitriles, esters, amides, oximes, and other fragrant compounds, and perfuming co-ingredients.

[0197] In certain embodiments, the solvents can include, but are not limited to, dipropylene glycol, propylene glycol, dieth-phthalate (DEP), diisononyl phthalate (DINP), benzyl benzoate, benzyl alcohol, iso propyl myristate (IPM), isopropyl palmitate (IPP / Deltyl Prime), butyl stearate, dioctyl adipate, tri ethyl citrate, methyl hydrogenated rosinate (CAS No. 8050-15-5), terpenes (e.g., Glidsol 100), paraffinic naphthenic solvent (e.g., LPA-170 Solvent), isoalkanes (e.g., Soltrol 170 Isoparaffin), isoparaffins, isooctadecanol (e.g., Tego Alkanol 66), phenoxyethanol, diethylene glycol monoethyl ether (Carbitol low gravity), glycol ether (Methyl Carbitol), Dipropylene Glycol Methyl Ether (e.g., Dowanol DPM), Dipropylene Glycol Methyl Ether Acetate (e.g., Dowanol DPMA), Propylene glycol methyl ether (e.g., Dowanol PM Glycol Ether), Tripropylene Glycol Methyl Ether, Diisoheptyl Phthalate (e.g., Jayflex® 77 available from Exxon), deionized or distilled water, specially denatured ethyl alcohol (e.g., SDA 40B), Dimethyl Adipate / Dimethyl Glutarate (e.g., DBE®-LVP Esters available from FLEXISOLV®), Racemic mixture (+ / -)-2,2-dimethyl-4-hydroxymethyl-l,3- di oxolane (e.g., Augo Clean Multi Solvent), Alcohol 40B Anhydrous 200 Proof, alcohol SDA 40B 190 Proof, Triacetin, 3 -Methoxy-3 -methyl- 1 -butanol (Solfit), Benzyl Laurate, Tripropylene Glycol Methyl Ether (e.g., Dowanol TPM), Dipropylene glycol n-butyl ether (e.g., Dowanol DPNB), Dimethyl siloxane, trimethylsiloxy-terminated (e.g., Dowanol Corning 200 Fluid), Caprylic / Capric Triglycerides (e.g., Neobee M-5), propylene glycol and glyceryl oleate (e.g., Arlacel 186), Uniceth-IC20L (e.g., Arlasolve 200 L), propanediol, 1, 3, Butyl Cellosolve, Hexylene glycol, Glycerine, N Methyl Stearate, Isopropyl alcohol, 2-Methyl-l,3- propanediol (e.g., MP Diol Glycol), Diethyl Citrate, Triethyl Acetyl Citrate, Isopentyldiacetate (IPD-AC), Dimethyl 2-methylpentanedioate (e.g., Rhodiasolv Iris), medium chain triglycerides (MTC), terpene hydrocarbons (e.g., Dipentene 5100), DL-limonene (e.g.,

[0198] ACTIVE 513686434.1 28 Attorney Docket No.: 071950.0475

[0199] Dipentene 122), 3, 5, 5 -trimethylhexyl acetate, Diethyl Malonate, Limonene (e.g., Unitene D), cyclohexyl acetate, para-tertiary-butyl (e.g., Vertenex), Ethyl Acetate, and Diethyl Succinate.

[0200] The accord compositions can be used in a fragrance composition for use in a consumer product. In particular embodiments, the consumer product is a hair care product. In certain embodiments, the consumer product is a shampoo. In particular embodiments, the fragrance composition can be used in a hair care product. In certain embodiments, the fragrance composition can be used in a shampoo.

[0201] In particular embodiments, the consumer product is a hair product or shampoo. The hair product is applied to the scalp to improve the scalp microbiome. In certain embodiments, a shampoo is applied to the scalp to improve the scalp microbiome.

[0202] To improve the scalp microbiome, the accord compositions in combination with the base of the consumer product increase bacterial load, decrease fungal load, and combinations thereof. In particular embodiments, the accord compositions in combination with the base of the consumer product increase the bacterial load on the scalp. In certain embodiments, the accord compositions in combination with the base of the consumer product increase the absolute abundance of C. acnes.

[0203] In particular embodiments, the accord compositions in combination with the base of the consumer product decrease the fungal load on the scalp. In certain embodiments, the accord compositions in combination with the base of the consumer product decrease the absolute abundance of at least one of AL restricta, Cladosporium sp., and AL globosa.

[0204] In certain embodiments, the accord compositions in combination with the base of the consumer product increase at least one bacteria species and decreases at least one fungi species. In particular embodiments, the accord compositions in combination with the base of the consumer product increase C. acnes and decrease Cladosporium sp. and AL globosa. In particular embodiments, the accord compositions in combination with the base of the consumer product increase C. acnes and decrease AL restricta and AL globosa. In particular embodiments, the accord compositions in combination with the base of the consumer product increase C. acnes and decrease at least one of AL restricta, Cladosporium sp., and AL globosa.

[0205] In particular embodiments, the accord compositions in combination with the base of the consumer product target at least one bacteria or fungi species to decrease sebum production, decrease scalp flakiness, decrease scalp malodor, decrease scalp irritation, decrease scalp sensitivity, increase hair growth, increase smoothness or silkiness, increase bounciness, increase overall hair quality, and combinations thereof.

[0206] ACTIVE 513686434.1 29 Attorney Docket No.: 071950.0475

[0207] In particular embodiments, the accord compositions in combination with the base of the consumer product target the bacteria S. epidermidis and the fungi M. restricta to improve at least one symptom selected from flakiness, itchiness, and malodor of the scalp. In particular embodiments, the accord compositions targets the bacteria S. epidermidis and the fungi M. restricta to improve at least one symptom selected from flakiness, itchiness, and malodor of the scalp. In certain embodiments, the accord compositions target the fungi M. restricta. In particular embodiments, the accord compositions target the bacteria S. epidermidis to improve at least one symptom selected from flakiness, itchiness, and malodor of the scalp.

[0208] In alternative embodiments, the accord compositions in combination with the base of the consumer product increase bacterial load, decrease fungal load, or a combination thereof to decrease sebum production, decrease scalp flakiness, decrease scalp malodor, decrease scalp irritation, decrease scalp sensitivity, increase hair growth, increase smoothness or silkiness, increase bounciness, increase overall hair quality, and combinations thereof. In particular embodiments, the accord compositions in combination with the base of the consumer product increase bacterial load to decrease sebum production, decrease scalp flakiness, decrease scalp malodor, decrease scalp irritation, decrease scalp sensitivity, increase hair growth, increase smoothness or silkiness, increase bounciness, increase overall hair quality, and combinations thereof. In certain embodiments, the accord compositions in combination with the base of the consumer product decrease fungal load to decrease sebum production, decrease scalp flakiness, decrease scalp malodor, decrease scalp irritation, decrease scalp sensitivity, increase hair growth, increase smoothness or silkiness, increase bounciness, increase overall hair quality, and combinations thereof. In particular embodiments, the accord compositions in combination with the base of the consumer product increase bacterial load and decrease fungal load to decrease sebum production, decrease scalp flakiness, decrease scalp malodor, decrease scalp irritation, decrease scalp sensitivity, increase hair growth, increase smoothness or silkiness, increase bounciness, increase overall hair quality, and combinations thereof. In certain embodiments, the accord compositions in combination with the base of the consumer product increase the bacterial-to-fungal ratio to decrease sebum production, decrease scalp flakiness, decrease scalp malodor, decrease scalp irritation, decrease scalp sensitivity, increase hair growth, increase smoothness or silkiness, increase bounciness, increase overall hair quality, and combinations thereof.

[0209] In certain embodiments, the accord compositions alone or in combination with the base of the consumer product increase C. acnes and decrease Cladosporium sp. and M. globosa resulting in a decrease of sebum production, decrease in scalp flakiness, decrease in scalp

[0210] ACTIVE 513686434.1 30 Attorney Docket No.: 071950.0475 malodor, decrease in scalp irritation, decrease in scalp sensitivity, increase in hair growth, increase in smoothness or silkiness, increase in bounciness, increase in overall hair quality, or combinations thereof.

[0211] In particular embodiments, the accord compositions can be used to improve the scalp microbiome. After application of the accord composition to the scalp, a reduction in fungal load and an increase in bacterial load.

[0212] In certain embodiments, the accord compositions in combination with the base of the consumer product results in an increase in the bacterial-to-fungal ratio, decrease in the fungal load, decrease in scalp flakiness, decrease scalp malodor, decrease scalp irritation, decrease scalp sensitivity, increase hair growth, increase smoothness or silkiness, increase bounciness, increase overall hair quality, and combinations thereof.

[0213] 5. Methods of Treating the Scalp Microbiome

[0214] A consumer product with an accord composition targets at least one bacteria or fungi species to treat the scalp microbiome. The consumer product increases bacterial load, decreases fungal load, and combinations thereof. This increases the bacterial-to-fungal ratio, where there is more bacteria species than fungi species on the scalp.

[0215] The fungi species are selected from the group consisting of Cladosporium halotolerans-sphaerospermum, Cladosporium sp, Malassezia arunalokei, Malassezia caprae, Malassezia globosa (M globosa), Malassezia reslricla. Malassezia slooffiae, Malassezia sp, Vishniacozyma taibaiensis, and combinations thereof. The bacteria species are selected from the group consisting of Cornyebacterium kroppenstedtii, Cutibacterium acnes (C. acnes), Cutibacterium humerusii, Gordonia terrae, Moraxella osloensis, Staphylococcus capitis- caprae, Staphylococcus caprae, Staphylococcus caprae-saccharolyticus, Stapphylococcus epidermis, Staphylococuccus saccharolyticus, L. clevelandensis, P. Uni, P. antartica, and combinations thereof. In certain embodiments, the consumer product or accord composition increase C. acnes and decrease Cladosporium sp. and AT. globosa.

[0216] In certain embodiments, the consumer product decreases sebum production, decreases scalp flakiness, decreases scalp malodor, decreases scalp irritation, decreases scalp sensitivity, increases hair growth, increases smoothness or silkiness, increases bounciness, increases overall hair quality, and combinations thereof.

[0217] The consumer product are applied to the scalp to treat or improve the scalp microbiome. After use of the consumer product, the bacterial-to-fungal ratio increases, so that there is a greater amount of bacteria species compared to fungi species on the scalp. In certain

[0218] ACTIVE 513686434.1 31 Attorney Docket No.: 071950.0475 embodiments, an increase in S. epidermidis and reduction M. restricta on the scalp is observed. In alternative embodiments, after use of the consumer product an increase C. acnes and decrease in Cladosporium sp. and M. globosa is observed. In addition, the consumer product improves at least one symptom selected from flakiness, itchiness, and malodor of the scalp. Further, the consumer product improves at least one of the ease of combing hair and hair shine. In alternative embodiments, the consumer product decreases sebum production, decreases scalp flakiness, decreases scalp malodor, decreases scalp irritation, decreases scalp sensitivity, increases hair growth, increases smoothness or silkiness, increases bounciness, increases overall hair quality, and combinations thereof.

[0219] EXAMPLES

[0220] The following examples are merely illustrative of the presently disclosed subject matter and they should not be considered as limiting the scope of the subject matter in any way.

[0221] Example 1

[0222] The minimum inhibition concentration (MIC) of amyl cinnamic aldehyde, citronellol, geraniol, laurinal, musk T, undecalactone G, and florol was measured alone and with hinokitiol to determine the compounds' synergy with hinokitiol.

[0223] In the presence of 1.94 ppm of hinokitiol, the MIC of amyl cinnamic aldehyde did not change; citronellol decreased, geraniol decreased, laurinal decreased, musk T decreased, undecalactone G did not change, and florol decreased, against M. restricta when compared to the MIC of the compounds alone. Similarly, in the presence of 3.9 ppm of hinokitiol, the MIC of amyl cinnamic aldehyde did not change, citronellol did not change, geraniol decreased, laurinal did not change, musk T decreased, undecalactone G decreased, and florol decreased, against S. epidermidis when compared to the MIC of the compounds alone.

[0224] Overall, hinokitiol showed synergy with geraniol, musk T, undecalactone gamma, and florol against S. epidermidis and with citronellol, geraniol, laurinal, musk T, and florol against M. restricta.

[0225] Example 2

[0226] Three accords, Accords A-C, were formulated using hinokitiol, a first synergistic compound, and additional synergistic compounds, shown below in Table 1. Accord D, the

[0227] ACTIVE 513686434.1 32 Attorney Docket No.: 071950.0475 control, was formulated using only additional synergistic compounds which are not active without the presence of hinokitiol.

[0228] Table 1.

[0229] The minimum inhibition concentration was measured for Accords A-D with both M. restricta and S. epidermidis (Figure 1). Accords A, B, and C were found to be active against M. restricta, Accords A and C were active against S. epidermidis, and Accord B was not active against S. epidermidis. Additional testing found Accords A, B, and C were active against M. globosa and C. acnes. Accord D was not active against M. restricta, S. epidermidis, and M. globosa, but was active against C. acnes.

[0230] Finally, the MIC of Accords A, B, and C with AT. restricta and S. epidermidis was measured when particular compounds were removed from the accord. Accord B was found to be active against AT restricta with no changes to the accord. Similarly, Accord C was found to be most active against both AT restricta and S. epidermidis without changes.

[0231] When hinokitiol or geraniol was removed from Accord A the MIC against AT restricta was comparable to the MIC with hinokitiol, while the MIC against S. epidermidis more than doubled. Removing both hinokitiol and geraniol resulted in a reduction in MIC against AT restricta and an MIC that more than doubled against S. epidermidis.

[0232] Further, when hinokitiol was removed from Accord B, the MIC against AT restricta and S. epidermidis was comparable. When geraniol was removed from Accord B, the MIC against AT restricta halved while MIC against S. epidermidis decreased by more than half. Removing both hinokitiol and geraniol resulted in a reduction in MIC against AT restricta and an MIC which more than doubled against S. epidermidis.

[0233] When the hinokitiol was removed from Accord C, the MIC doubled with AT restricta and more than quadrupled with S. epidermidis. When geraniol was removed, the MIC

[0234] ACTIVE 513686434.1 33 Attorney Docket No.: 071950.0475 doubled with M. restricta, while a reduction in MIC was observed with S. epidermidis. Removal of both geraniol and hinokitiol from Accord C resulted in an MIC comparable to Accord C with M. restricta while the MIC more than quadrupled with S. epidermidis. When musk T, was removed, the MIC with M. restricta was comparable to Accord C while the MIC with S. epidermidis more than quadrupled. Similarly, when both hinokitiol and musk T were removed, the MIC with M. restricta was comparable to Accord C while the MIC with S. epidermidis more than quadrupled.

[0235] Next, the MIC of Accords A, B, and C was measured when the amount of hinokitiol in the formulation was adjusted as shown in Table 2.

[0236] Table 2.

[0237] Overall, Accord A was active against S. epidermidis when hinokitiol was maintained at 5% and active against M. restricta at 0.25% and 1% to 5%, by weight of the accord composition. Similarly, Accord B was active against S. epidermidis when hinokitiol is present from 1% to 2.5% and active against AT. restricta when hinokitiol is present from 1% to 5% or less than 0.125%. Finally, Accord C was active against S. epidermidis and AT. restricta when maintaining hinokitiol at 5%.

[0238] Thus, the hinokitiol, a first synergistic compound, and additional synergistic compounds are all necessary to maintain the properties of Accord C.

[0239] Example 3

[0240] Two shampoos were formulated with Accord C and Accord D. In this study, 44 women ages 35-59 who washed their hair more than 3 times a week, were provided with a

[0241] ACTIVE 513686434.1 34 Attorney Docket No.: 071950.0475 shampoo with 1% of Accord C as the active shampoo and shampoo with 1% of Accord D as the placebo shampoo. Of the 44 participants, 50% had an oily scalp with sebum secretion greater than 100 pg / cm2, and 50% had a dry scalp with a sebum secretion of less than 100 pg / cm2.

[0242] After four weeks of placebo used, the participants washed their hair using the active shampoo for four weeks. Between use of the placebo and active shampoo, participants performed a washout of all hair products for 24 hours. At 0 weeks, 4 weeks, and 8 weeks, microbiome, scalp sebum, and scalp flake samples are collected. The microbiome was collected from the participants hairline using a swab. Scalp sebum excreted was measured using a Sebumeter® SM 815 (Courage & Khazaka). The measurement was performed approximately 3 cm from the middle of the ear for about 30 seconds. Flakiness was assessed by the presence of dandruff flakes that are adhering to the scalp skin using Adherent Scalp Flaking Score (ASFS). A comb was used to part the hair in 8 sections to give a clear view of the scalp. Loose flakes in the hair were not considered in the grading and the final, or total, ASFS is the sum of the grades for all 8 scalp sections.

[0243] In addition, self-report surveys were completed by the participants where participants evaluated sebum production, scalp flakiness, scalp malodor, scalp irritation, scalp sensitivity, hair growth, smoothness or silkiness, bounciness, and good hair days.

[0244] At the conclusion of the study, bacterial and fungal load on the scalp microbiome was analyzed. As seen in Fig. 2, there was a significant shift on the scalp bacterial to fungal ratio after active shampoo use.

[0245] In addition, there was significant increase in bacterial load after both placebo shampoo and active shampoo use, when compared to the baseline (Fig. 3A). When further delineated by dry and oily scalps, a strong shift in oily scalp conditions was observed. In fact, the change in bacterial load for oily scalp participants was statistically significant. While a similar trend was observed for dry scalps, the shift was less pronounced (Fig. 3B).

[0246] Further, there was significant decrease in fungal load after the active shampoo use across all participants, when compared to the baseline and placebo shampoo samples (Fig. 4A). Similarly, there was a significant shift in fungal load for both dry and oily scalps (Fig. 4B).

[0247] The Shannon diversity index of both the bacterial and fungal loads was then analyzed for the baseline sample, placebo shampoo sample, and active shampoo sample. Overall, no significant change was observed for the bacterial alpha diversity (Fig. 5A) and the fungal alpha diversity (Fig. 5B). In addition, there was no significant change in bacterial composition (Fig. 6A) and fungal composition (Fig. 6B).

[0248] ACTIVE 513686434.1 35 Attorney Docket No.: 071950.0475

[0249] The change in the top 10 bacteria and fungi was then analyzed. Overall, there was no change in the top 10 bacteria, although an increased abundance of C. acnes was observed (Fig. 7A-B). There was a significant shift in relative abundance as well as absolute abundance in the top ten fungal taxa after the use of the active shampoo (Fig. 7C-D). Cladosporium sp (p<0.01) and M. globosa (p<0.05) significantly decreased after active used compared to placebo use. Further, M. globosa (p<0.01) and AT. arunalokei (p<0.01), as well as other fungi (p<0.05), significantly decreased from baseline to active usage. Although not significant, there was a decrease in absolute abundance ofM. restricta. These changes were comparable between oily and dry scalp participants (Fig. 7E-F).

[0250] In addition, scalp sebum for both oil and dry scalps was measured at 0, 4, and 8 weeks. At 4 weeks, after use of the placebo shampoo, oily scalp sebum decreased 24%, while dry scalp sebum increased 84%. After an additional 4 weeks with active shampoo use, there was no significant change in scalp sebum when compared scalp sebum levels after placebo shampoo use. After the full 8 weeks, oily scalp sebum decreased 26% and dry scalp sebum increased 69%.

[0251] The Adherent Flaking Score of the dry and oily scalps was then assessed over the 8 week period. The flaking score for both dry and oil scalps decreased over 95.5% with the use of active shampoo. This reduction in flakiness shows a significant correlation with the discussed microbial changes, specifically the reduction of M. restricta (Fig. 8A). While the increase of C. acnes is associated with a decrease in flakiness, there was not a significant correlation (Fig. 8B). In fact, the dry scalp decreased 100% when compared to the baseline. Conversely, after placebo use, less than a 50% decrease was observed (Fig. 8C).

[0252] Finally, participants were asked to self-report on various experiences after using the placebo and active shampoo. Participants were asked to indicate if they did not have pillowcase odor, fizziness, dryness, flakiness, irritation, itchiness, odor, oiliness, redness, sensitivity, and inflammation at 0, 4, and 8 weeks (Figs. 9A and 9B). For both oily and dry scalps, inflammation and redness improved over 90%, irritation improved over 80%, and sensitivity improved over 70%. In addition, more than 60% of participants reported an improvement in scalp odor.

[0253] The participants were additionally asked to list evaluate of fullness and thickness, bounciness and movement, hair growth, moisturization, shine, softness, thickness, manageability / ease of combing, and how many good hair days, and at 0, 4, and 8 weeks (Fig. 10A and 10B). Overall, oily scalps had a higher improvement in positive symptoms, with a more than 50% in hair bounciness and great hair days, and a 23% increase in growth, shine, and softness.

[0254] ACTIVE 513686434.1 36 Attorney Docket No.: 071950.0475

[0255] Finally, the participants were asked the following questions:

[0256] Please share your experience with the shampoo you used in the last 7 days.

[0257] Think about how shampoo has affected your everyday life.

[0258] What notable changes have there been? How well do you think the product fights malodor?

[0259] If you could take one benefit from this product and add it to your “usual routine ” what would it be?

[0260] The frequency of certain phrases used by the participants was quantified. The number of participants who used particular phrases is shown in Table 3.

[0261] Table 3.

[0262] Overall, after active shampoo use an increase in the bacterial to fungal ratio, bacterial load, and fungal load was observed. Notably, change bacterial load was dependent on scalp sebum, while change in fungal load was not dependent on scalp sebum. Further, sebum decreased for placebo and active shampoo use while flakiness decreased after active use only. While a mild decrease in malodor, irritation, and redness / inflammation, and an increase in hair growth, smoothness / silkiness, bounce, and great hair days was observed after placebo use, a greater decrease in malodor, irritation, and redness / inflammation, as well as sensitivity and an

[0263] ACTIVE 513686434.1 37 Attorney Docket No.: 071950.0475 increase in hair growth, smoothness / silkiness, bounce, and great hair was observed after active shampoo use.

[0264] Example 4

[0265] Two accords, Accords E and F were formulated using hinokitiol, a first synergistic compound, and additional synergistic compounds, shown below in Table 4. Accord G, the control, was formulated using only additional synergistic compounds which are not active without the presence of hinokitiol.

[0266] Table 4.

[0267] The Accords were then added to fragrance compositions, as shown in Table 5. These are added to a suitable consumer product.

[0268] Table 5.

[0269] Example 5

[0270] Two accords, Accords H and I, are formulated using hinokitiol, a first synergistic compound, and additional synergistic compounds, shown below in Table 6.

[0271] ACTIVE 513686434.1 38 Attorney Docket No.: 071950.0475

[0272] Table 6.

[0273] Example 6

[0274] Fragrance compositions, Compositions D-G, are formulated as shown below in Table 7. Compositions D-G include a first accord composition, a second accord composition, and at least one compound which synergizes hinokitiol to M. restricted additional fragrance compounds, and solvent.

[0275] Table 7.

[0276] The Compositions D-G are added to a consumer product, such as a shampoo, in an amount of 0.6 wt.%.

[0277] In addition to the various embodiments depicted and claimed, the disclosed subject matter is also directed to other embodiments having other combinations of the features disclosed and claimed herein. As such, the particular features presented herein can be combined with each other in other manners within the scope of the disclosed subject matter such that the disclosed subject matter includes any suitable combination of the features disclosed herein. The

[0278] ACTIVE 513686434.1 39 Attorney Docket No.: 071950.0475 foregoing description of specific embodiments of the disclosed subject matter has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the disclosed subject matter to those embodiments disclosed.

[0279] It will be apparent to those skilled in the art that various modifications and variations can be made in the systems and methods of the disclosed subj ect matter without departing from the spirit or scope of the disclosed subject matter. Thus, it is intended that the disclosed subject matter include modifications and variations that are within the scope of the appended claims and their equivalents.

[0280] Various patents and patent applications are cited herein, the contents of which are hereby incorporated by reference herein in their entireties.

[0281] ACTIVE 513686434.1 40

Claims

Attorney Docket No.: 071950.0475WHAT IS CLAIMED IS:

1. An accord composition for improving the scalp microbiome comprising hinokitiol and at least one synergistic compound.

2. The accord composition of claim 1, wherein hinokitiol is present in the accord composition in an amount of from about 0.1% to about 20% by weight of the accord composition.

3. The accord composition of claim 1, wherein the at least one synergistic compound is present in the accord composition in an amount of 50% to about 99.9% by weight of the accord composition.

4. The accord composition of claim 1, wherein the at least one synergistic compound is present in the accord composition in an amount of 0.01% to about 50% by weight of the accord composition.

5. The accord composition of claim 1, wherein the at least one synergistic compound comprises a first synergistic compound and at least one additional synergistic compound.

6. The accord composition of claim 5, wherein the first synergistic compound is present in an amount of from about 0.1% to about to about 75% by weight of the accord composition.

7. The accord composition of claim 5, wherein the at least one additional synergistic compound is present in an amount of from about 25% to about 70% by weight of the accord composition.

8. The accord composition of claims 5 and 6, wherein the first synergistic compound is geraniol or musk T.

9. The accord composition of claim 8, wherein the first synergistic compound is geraniol.

10. The accord composition of claims 5 and 7, wherein the at least one additional synergistic compounds are selected from the group consisting of beta-ionone, aldehyde C-8, citral, 1- dihydro citronellol, heptanoic acid, nonadien-l-ol-trans-2-Cis 6, caprylic acid,ACTIVE 513686434.1 41Attorney Docket No.: 071950.0475 undecalactone gamma, decalactone delta, benzyl phenyl acetate, hexyl cinnamic aldehyde, phenyl ethyl alcohol, thymol, laurinal, florol, alcohol C-12, alcohol C-8, L-citronellal, geraniol, musk T, nutmeg oil, pinene beta, linalool, and citronellol.

11. The accord composition of claim 10, wherein the at least one additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T.

12. The accord composition of claim 10, wherein the at least one additional synergistic compounds are amyl cinnamic aldehyde, undecalactone G, florol, citronellol, and musk T.

13. The accord composition of claims 1-12, wherein the composition targets at least one bacteria or fungi species.

14. The accord composition of claim 13, wherein the fungi species are selected from the group consisting of Cladosporium halotolerans-sphaerospermum (C. halotolerans- sphaerospermum), Cladosporium sp, Malassezia arunalokei (M. arunalokei), Malassezia caprae (M. caprae), Malassezia globosa (M. globosa), Malassezia restricta (M reslricla . Malassezia slooffiae (M slooffiae), Malassezia sp, Vishniacozyma taibaiensis (V. taibaiensis), and combinations thereof.

15. The accord composition of claim 13, wherein the bacteria species are selected from the group consisting of Corny ebacterium kroppenstedtii (C. kroppenstedtii), Cutibacterium acnes (C. acnes), Cutibacterium humerusii (C. humerusii), Gordonia terrae (G. terrae), Moraxella osloensis (M osloensis), Staphylococcus capitis-caprae (S. capitis-caprae), Staphylococcus caprae (S. caprae), Staphylococcus caprae-saccharolyticus (S. caprae- saccharolyticus) , Stapphylococcus epidermis (S. epidermidis), Staphylococuccus saccharolyticus (S. capitis- saccharolyticus), L. clevelandensis, P. Uni, P. antartica and combinations thereof.

16. A consumer product for improving scalp microbiome comprising: a) a consumer product base; and b) an accord composition; wherein the accord comprises hinokitiol and at least one synergistic compound.ACTIVE 513686434.1 42Attorney Docket No.: 071950.047517. The consumer product of claim 16, wherein hinokitiol is present in the accord composition in an amount of from about 0.1% to about 20% by weight of the accord composition.

18. The accord composition of claim 16, wherein the at least one synergistic compound is present in the accord composition in an amount of 50% to about 99.9% by weight of the accord composition.

19. The accord composition of claim 16, wherein the at least one synergistic compound is present in the accord composition in an amount of 0.01% to about 50% by weight of the accord composition.

20. The consumer product of claim 16, wherein the at least one synergistic compound comprises a first synergistic compound and at least one additional synergistic compound.

21. The consumer product of claim 20, wherein the first synergistic compound is present in an amount of from about 0.1% to about to about 75% by weight of the accord composition.

22. The consumer product of claim 20, wherein the at least one additional synergistic compound is present in an amount of from about 25% to about 70% by weight of the accord composition.

23. The consumer product of claims 20 and 21, wherein the first synergistic compound is geraniol or musk T.

24. The consumer product of claim 23, wherein the first synergistic compound is geraniol.

25. The consumer product of claims 20 and 22, wherein the at least one additional synergistic compounds are selected from the group consisting of amyl cinnamic aldehyde, undecalactone G, florol, citronellol, laurinal, and musk T.

26. The consumer product of claims 16-25, wherein the accord composition is present in the composition in an amount of about 0.01% to about 10% by weight of the consumer product.ACTIVE 513686434.1 43Attorney Docket No.: 071950.047527. The consumer product of claim 26, wherein the consumer product is selected from the group consisting shampoos, conditioners, dry shampoos, hair masks, hair oils, hair serums, hair wax, hair pomade, hair gel, hair cream, hair creme, hair clay, hair powders, hair mousse, hair lotion, hair musk, hair texturizer, heat protectant spray, sea salt spray, scalp lotion, and combinations thereof.

28. A method for improving the scalp microbiome, comprising treating the scalp with the consumer product of claims 16-27.

29. The method of claim 26, wherein after treating the scalp with the consumer product the bacterial-to-fungal ratio of the scalp is increased.

30. The method of claim 29, wherein the fungi species are selected from the group consisting of Cladosporium halotolerans-sphaerospermum (C. halotolerans-sphaerospermum), Cladosporium sp, Malassezia arunalokei (M arunalokei), Malassezia caprae (M. caprae), Malassezia globosa (M globosa), Malassezia restricta (M. reslricla . Malassezia slooffiae (M slooffiae), Malassezia sp, Vishniacozyma taibaiensis (V. taibaiensis), and combinations thereof.

31. The method of claim 29, wherein the bacteria species are selected from the group consisting of Corny ebacterium kroppenstedtii (C kroppenstedtii), Cutibacterium acnes (C. acnes), Cutibacterium humerusii (C humerusii), Gordonia terrae (G. terrae), Moraxella osloensis (M osloensis), Staphylococcus capitis-caprae (S. capitis-caprae), Staphylococcus caprae (S. caprae), Staphylococcus caprae-saccharolyticus (S. caprae-saccharolyticus) , Stapphylococcus epidermis (S. epidermidis), Staphylococuccus saccharolyticus (S. capitis- saccharolyticus), L. clevelandensis, P. Uni, P. antartica and combinations thereof.

32. The method of claims 28-31, wherein after treating the scalp with the consumer product there is a decrease in sebum production, decrease in scalp flakiness, decrease in scalp malodor, decrease in scalp irritation, decrease in scalp sensitivity, increase in hair growth, increase in smoothness or silkiness, increase in bounciness, increase in overall hair quality, and combinations thereof.ACTIVE 513686434.1 44

Images